Research & Reviews: Journal of Pharmaceutical Analysis e-ISSN: 2320-0812

Advances in Computational Modelling of Drug Absorption: Enhancing Drug Development and Bioavailability

Kiran Bajwa*

Department of Pharmaceutical Analysis, Jamia Hamdard University, New Delhi, India

Short Communication

Received: 26-Aug-2024, Manuscript No. JPA-24-150817; **Editor assigned:** 28-Aug-2024, PreQC No. JPA-24-150817 (PQ); **Reviewed:** 11-Sep-2024, QC No. JPA-24-150817; **Revised:** 17-Sep-2024, Manuscript No. JPA-24-150817 (R); **Published:** 23-Sep-2024, DOI: 10.4172/2320-0812.13.3.010

***For Correspondence:**
Kiran Bajwa, Department of Pharmaceutical Analysis, Jamia Hamdard University, New Delhi, India

E-mail: bajwakiran@gmail.com

Citation: Bajwa K. Advances in Computational Modelling of Drug Absorption: Enhancing Drug Development and Bioavailability. RRJ Pharm Anal. 2024;13:010.

DESCRIPTION

Drug absorption is a critical aspect of pharmacokinetics that determines the bioavailability of therapeutic agents. Understanding how drugs are absorbed in the body is essential for drug development, formulation design and optimizing therapeutic efficacy. With advancements in computational technologies, modelling drug absorption has become increasingly sophisticated, enabling researchers to predict absorption characteristics and make informed decisions in pharmaceutical sciences. This article discusses the various computational approaches used in modelling drug absorption and their implications for drug development.

Determining drug dissolve

Drug absorption refers to the process by which a drug enters the systemic circulation after administration. It is influenced by various factors, including the drug's physicochemical properties, the formulation's characteristics and physiological conditions within the Gastro Intestinal (GI) tract. The rate and extent of absorption directly impact the drug's efficacy and safety, making it a critical focus in pharmaceutical research [1-3].

Importance of modelling drug absorption

Formulation development: Understanding absorption mechanisms allows for the optimization of formulations to enhance bioavailability [4].

Drug design: Predictive modelling can guide the design of new compounds with improved absorption properties.

Regulatory compliance: Regulatory agencies often require absorption data to evaluate drug safety and efficacy.

Personalized medicine: Computational models can account for individual variability, aiding in personalized drug therapy.

computational approaches to modelling drug absorption

Several computational methods are used to model drug absorption, each with its strengths and limitations. Here are some of the most widely employed approach [5].

Physiologically-Based Pharmacokinetic (PBPK) Modelling

PBPK modelling is a powerful tool that incorporates physiological parameters to simulate drug absorption, distribution, metabolism and excretion. It uses a compartmental approach to represent different organs and tissues in the body. PBPK models can predict the impact of physiological changes (e.g., age, disease) on drug absorption and disposition [6].

Applications: PBPK models are particularly useful for assessing drug-drug interactions and understanding the effects of formulation changes on absorption.

In *Vitro-In Vivo* Correlation (IVIVC)

IVIVC is a computational technique that correlates in *vitro* drug release data with in vivo absorption data. By establishing a mathematical relationship between these two parameters, researchers can predict how changes in formulation will affect absorption [7].

Applications: Widely used in the development of oral dosage forms to ensure consistent bioavailability across different formulations.

Quantitative Structure-Activity Relationship (QSAR) models

QSAR models analyse the relationship between the chemical structure of a drug and its absorption properties. By using statistical and machine learning techniques, researchers can predict the absorption characteristics of new compounds based on their molecular features [8].

Applications: QSAR models are useful for screening large compound libraries and identifying candidates with favourable absorption profiles.

Computational Fluid Dynamics (CFD)

CFD is a simulation technique that models fluid flow and transport phenomena. In the context of drug absorption, CFD can be used to simulate the movement of drug formulations through the GI tract, providing insights into how flow patterns and shear forces influence absorption [9].

Applications: CFD is valuable for optimizing formulation parameters, such as viscosity and particle size, to enhance drug absorption.

Machine Learning and Artificial Intelligence (AI)

Machine learning and AI have emerged as powerful tools in drug absorption modelling. These approaches leverage large datasets to identify patterns and relationships that traditional methods may overlook. By training algorithms on existing absorption data, researchers can develop predictive models that inform drug design and formulation strategies [9].

Applications: AI-based models can rapidly assess the absorption potential of new compounds and help optimize formulations in a more efficient manner.

Challenges and restrictions

While computational modelling has revolutionized our understanding of drug absorption, several challenges remain:

Data quality: The accuracy of predictive models depends on the quality and quantity of input data. Limited or poor-quality datasets can lead to unreliable predictions.

Complexity of biological systems: The human body is a complex system with numerous interacting factors. Simplifying these interactions for modelling can sometimes overlook critical variables [10].

Regulatory acceptance: While computational approaches are gaining traction, regulatory agencies may still prefer traditional methods for certain assessments. Establishing guidelines for the acceptance of computational models is essential for their widespread application.

Upcoming instructions

The field of computational modelling in drug absorption is rapidly evolving. upcoming instructions may include.

Integration of multi-omics data: Incorporating genomic, proteomic and metabolomics data can enhance the predictive capabilities of absorption models and facilitate personalized medicine.

Enhanced machine learning techniques: As machine learning algorithms become more developed, they can provide deeper insights into the factors influencing drug absorption and help identify novel drug candidates.

Collaboration across disciplines: Interdisciplinary collaboration among pharmacologists, chemists and data scientists will drive innovation in modelling approaches, leading to better drug development strategies.

REFERENCES

1. Dahlgren D, et al. Intestinal permeability and drug absorption: Predictive experimental, computational and in *vivo* approaches. Pharmaceutics. 2019;11:411.
2. Brouwers J, et al. Resolving intraluminal drug and formulation behavior: Gastrointestinal concentration profiling in humans. Eur J Pharm Sci. 2014;61:2-10.
3. Thelen K, et al. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: Oral solutions. J Pharm Sci. 2011;100:5324-5345.
4. Sugano K. Introduction to computational oral absorption simulation. Expert Opin Drug Metab Toxicol.2009;5:259-293.
5. Wang T. Quantitative structure-activity relationship: Promising advances in drug discovery platforms. Expert Opin Drug Discov. 2015;10:1283-1300.
6. Sager JE. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification. Drug Metab Dispos.2015;43:1823-1827.
7. Jacob S, et al. An updated overview with simple and practical approach for developing in *vitro-in vivo* correlation. Drug Dev Res. 2018;79:97-110.
8. Yang GF. Development of quantitative structure-activity relationships and its application in rational drug design. Curr Pharm Des. 2006;12:4601-4611.
9. Lipka E. Setting bioequivalence requirements for drug development based on preclinical data: Optimizing oral drug delivery systems. J Control Release. 1999;62:41-49.
10. Borsadia S. Factors to be considered in the evaluation of bioavailability and bioequivalence of topical formulations. Skin Pharmacol. 1992;5:129-145.